U.S. drug prices to rise for 350 medications in 2026

Pharmaceutical companies are planning to increase the U.S. prices of over 350 branded medications, including vaccines and cancer treatments. This number is higher than last year, with the median price hike around 4%. These price increases don't consider discounts offered to pharmacy benefit managers. Although the majority of drugs are seeing price hikes, nine drugs will have their list prices cut, including a significant reduction for the diabetes drug Jardiance. These price adjustments occur despite ongoing pressure from the Trump administration to lower drug costs for Americans, who currently pay the highest prices globally. Many pharmaceutical companies, even those involved in deals with the government, are still raising prices on other medications. Experts suggest these actions offer minimal overall impact on high prescription drug costs. Pfizer leads with the most price increases this year. Company statements justify these increases as necessary for investment and innovation, aligning with or below inflation. However, the changes may be more modest than in the past, thanks to increased government scrutiny and new policies. Further price adjustments are anticipated in the coming months.